Pregled bibliografske jedinice broj: 376494
Is an antioxidative capacity of HI-6 oxime a key factor to improve the therapy with irinotecan?
Is an antioxidative capacity of HI-6 oxime a key factor to improve the therapy with irinotecan? // Toxicolgy Letters, Abstracts of the 45th Congress of the European Societies of Toxicology / Tsatsakis, Aristidis M., Liesivuori, Jyrki (ur.).
Rodos, Grčka, 2008. (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 376494 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Is an antioxidative capacity of HI-6 oxime a key factor to improve the therapy with irinotecan?
Autori
Suzana Berend, Ana Lucić Vrdoljak, Božica Radić, Jasenka Piljac-Žegarac, Marin Mladinić, Davor Želježić, Nevenka Kopjar
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Toxicolgy Letters, Abstracts of the 45th Congress of the European Societies of Toxicology
/ Tsatsakis, Aristidis M., Liesivuori, Jyrki - , 2008
Skup
45th Congress of the European Societies of Toxicology
Mjesto i datum
Rodos, Grčka, 05.10.2008. - 08.10.2008
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
HI-6; irinotecan; antioxidative capacity
Sažetak
New and improved therapy modalities currently employed in the management of malignant diseases significantly contribute to the overall survival rate in cancer patients. Therefore, some compounds although not primarily designed as supportive drugs in chemotherapy, are promising candidates for possible clinical use. Our in vitro and in vivo experiments have demonstrated that HI-6 could “ protect” cholinesterases against the irinotecan, one of frequently used antineoplastic drugs, and in that way a part of cholinergic symptoms might be reduced. Interestingly, certain antioxidants may counteract the effects of chemotherapy-induced oxidative stress on the cell cycle and enhance the cytotoxicity of antineoplastic agents. So with the purpose to investigate the levels of oxidative stress and DNA damage (lipid peroxidation, the alkaline comet assay and micronucleus assay) related to treatments with irinotecan and HI-6 given alone or in combination we also focused on the assessment of possible antioxidative capacity of HI-6. In view of the DPPH assay results, HI-6 shows moderate radical scavenging at the tested concentration. Administration of HI-6 alone or with irinotecan diminished the levels of TBARS in rat plasma. Confirmatory results regarding HI-6 efficacy were also obtained by the alkaline comet and micronucleus assay. When given alone, it mostly did not induce significant disturbances in the level of primary DNA damage in somatic cells of treated rats and did not significantly induce the formation of micronuclei. Results obtained in the present study seems to be a proper argument to consider HI-6 as beneficial substance during chemotherapy.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
022-0222148-2137 - Genotoksičnost kemijskih i fizikalnih agensa prirodnog i antropogenog podrijetla (Kašuba, Vilena, MZOS ) ( CroRIS)
022-0222148-2139 - Terapijski učinak novosintetiziranih spojeva pri otrovanju organofosfatima (Lucić Vrdoljak, Ana, MZOS ) ( CroRIS)
098-0982913-2829 - Molekularna regulacija biljnog razvitka (Salopek-Sondi, Branka, MZOS ) ( CroRIS)
Ustanove:
Institut za medicinska istraživanja i medicinu rada, Zagreb,
Institut "Ruđer Bošković", Zagreb
Profili:
Davor Želježić
(autor)
Ana Lucić Vrdoljak
(autor)
Božica Radić
(autor)
Marin Mladinić
(autor)
Jasenka Piljac Žegarac
(autor)
Suzana Žunec
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE